Fmoc-Thr(tBu)-olCAS# 189337-28-8 |
- PF-4708671
Catalog No.:BCC5031
CAS No.:1255517-76-0
- BIX 02565
Catalog No.:BCC4303
CAS No.:1311367-27-7
- BI-D1870
Catalog No.:BCC5030
CAS No.:501437-28-1
- CMK
Catalog No.:BCC1489
CAS No.:821794-90-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 189337-28-8 | SDF | Download SDF |
| PubChem ID | 11143467 | Appearance | Powder |
| Formula | C23H29NO4 | M.Wt | 383.48 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 9H-fluoren-9-ylmethyl N-[(2R,3R)-1-hydroxy-3-[(2-methylpropan-2-yl)oxy]butan-2-yl]carbamate | ||
| SMILES | CC(C(CO)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13)OC(C)(C)C | ||
| Standard InChIKey | LBVPBNDGSCZOTB-QVKFZJNVSA-N | ||
| Standard InChI | InChI=1S/C23H29NO4/c1-15(28-23(2,3)4)21(13-25)24-22(26)27-14-20-18-11-7-5-9-16(18)17-10-6-8-12-19(17)20/h5-12,15,20-21,25H,13-14H2,1-4H3,(H,24,26)/t15-,21-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Fmoc-Thr(tBu)-ol Dilution Calculator
Fmoc-Thr(tBu)-ol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.6077 mL | 13.0385 mL | 26.077 mL | 52.154 mL | 65.1924 mL |
| 5 mM | 0.5215 mL | 2.6077 mL | 5.2154 mL | 10.4308 mL | 13.0385 mL |
| 10 mM | 0.2608 mL | 1.3038 mL | 2.6077 mL | 5.2154 mL | 6.5192 mL |
| 50 mM | 0.0522 mL | 0.2608 mL | 0.5215 mL | 1.0431 mL | 1.3038 mL |
| 100 mM | 0.0261 mL | 0.1304 mL | 0.2608 mL | 0.5215 mL | 0.6519 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Fmoc-Thr(tBu)-ol
- 3'-Methoxyrocaglamide
Catalog No.:BCN1171
CAS No.:189322-69-8
- 3'-Hydroxyrocaglamide
Catalog No.:BCN1170
CAS No.:189322-67-6
- Xanthohumol B
Catalog No.:BCN8018
CAS No.:189308-10-9
- Danshenol B
Catalog No.:BCN2616
CAS No.:189308-09-6
- Danshenol A
Catalog No.:BCN3145
CAS No.:189308-08-5
- N-Caffeoyl-O-methyltyramine
Catalog No.:BCC8216
CAS No.:189307-47-9
- Isotanshinone IIB
Catalog No.:BCN2513
CAS No.:109664-01-9
- Delafloxacin
Catalog No.:BCC1522
CAS No.:189279-58-1
- Eucalyptolic acid
Catalog No.:BCN3246
CAS No.:189272-68-2
- Cleroindicin F
Catalog No.:BCN1169
CAS No.:189264-47-9
- Cleroindicin D
Catalog No.:BCN1168
CAS No.:189264-45-7
- Cleroindicin C
Catalog No.:BCN1167
CAS No.:189264-44-6
- Corchoionol C
Catalog No.:BCN1172
CAS No.:189351-15-3
- Endomorphin-1
Catalog No.:BCC1008
CAS No.:189388-22-5
- Triptinin B
Catalog No.:BCN6785
CAS No.:189389-05-7
- Chebulinic acid
Catalog No.:BCN3263
CAS No.:18942-26-2
- Boc-Cys(pMeOBzl)-OH
Catalog No.:BCC3378
CAS No.:18942-46-6
- Boc-D-Phe-OH
Catalog No.:BCC3433
CAS No.:18942-49-9
- Boc-Ser(tBu)-OH.DCHA
Catalog No.:BCC3445
CAS No.:18942-50-2
- Epothilone D
Catalog No.:BCC1554
CAS No.:189453-10-9
- Ginsenoside F5
Catalog No.:BCN6419
CAS No.:189513-26-6
- Pinostrobin chalcone
Catalog No.:BCN1173
CAS No.:18956-15-5
- 6'-Hydroxy-7'-ethoxybergamottin
Catalog No.:BCC8306
CAS No.:
- Dihydrooroxylin A
Catalog No.:BCN3500
CAS No.:18956-18-8
Conventional and high-yield synthesis of DTPA-conjugated peptides: application of a monoreactive DTPA to DTPA-D-Phe1-octreotide synthesis.[Pubmed:9177852]
Bioconjug Chem. 1997 May-Jun;8(3):442-6.
Successful imaging of somatostatin receptor-positive tumors with 111In-DTPA-D-Phe1-octreotide has stimulated development of peptide radiopharmaceuticals using DTPA as the chelating agent. However, use of cyclic DTPA dianhydride (cDTPA) resulted in low synthetic yields of DTPA-peptide by either solution or solid-phase syntheses. This paper reports a novel high-yield synthetic procedure for DTPA-D-Phe1-octreotide that is applicable to other peptides of interest using a monoreactive DTPA derivative. A monoreactive DTPA that possesses one free terminal carboxylic acid along with four carboxylates protected with tert-butyl ester (mDTPA) was synthesized. Fmoc-Thr(tBu)-ol, prepared from Fmoc-Thr(tBu)-OH, was loaded onto 2-chlorotrityl chloride resin. After construction of the peptide chains by Fmoc chemistry, mDTPA was coupled to the alpha amine group of the peptide on the resin in the presence of 1,3-diisopropylcarbodiimide and 1-hydroxybenzotriazole. Treatment of the mDTPA-peptide-resin with trifluoroacetic acid-thioanisole removed the protecting groups and liberated [Cys(Acm)2,7]-octreotide-D-Phe1-DTPA from the resin. Iodine oxidation of the DTPA-peptide, followed by the reversed-phase HPLC purification, produced DTPA-D-Phe1-octreotide in overall 31.8% yield based on the starting Fmoc-Thr(tBu)-ol-resin. The final product gave a single peak on analytical HPLC, and amino acid analysis and mass spectrometry confirmed the integrity of the product. 111In radiolabeling of the product provided 111In-DTPA-D-Phe1-octreotide with > 95% radiochemical yield, as confirmed by analytical reversed-phase HPLC, TLC, and CAE. These finding indicated that use of mDTPA during solid-phase peptide synthesis greatly increased the synthetic yield of DTPA-D-Phe1-octreotide, due to the absence of nonselective reactions that are unavoidable when cDTPA is used. These results also suggested that mDTPA would be a versatile reagent to introduce DTPA with high yield into peptides of interest.
